{
  "id": "finasteride",
  "title": "Finasteride",
  "lang": "en",
  "source_lang": "en",
  "summary": "Finasteride is a prescription 5-alpha-reductase inhibitor used primarily to treat benign prostatic hyperplasia and male-pattern hair loss.",
  "category": "health",
  "subcategory": "drugs",
  "type": "concept",
  "aliases": [],
  "generated_at": "2026-11-06",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/finasteride/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/finasteride/",
      "json": "https://aiwiki.page/zh/finasteride.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Finasteride is a prescription medication that reduces the formation of dihydrotestosterone (DHT), an androgen involved in prostate growth and male-pattern hair loss. It belongs to the 5-alpha-reductase inhibitor class and is used primarily for benign prostatic hyperplasia and male androgenetic alopecia. Its benefits develop over months rather than immediately. Important safety considerations include sexual adverse effects, psychiatric adverse effects, altered interpretation of prostate-specific antigen measurements, and potential harm to a developing male fetus."
    },
    {
      "heading": "Mechanism of action",
      "text": "Finasteride inhibits 5-alpha-reductase, the enzyme that converts testosterone into DHT. It acts predominantly on the type II form of the enzyme, which is present in tissues including the prostate and hair follicles.\n\nDHT activates androgen receptors and contributes to growth of prostate tissue. In genetically susceptible scalp follicles, it promotes progressive follicular miniaturization: hairs become finer, shorter, and less visible. Lowering DHT can therefore reduce prostate volume and slow or partially reverse androgen-related follicular miniaturization.\n\nFinasteride does not directly block the androgen receptor and does not suppress testosterone production in the same way as treatments that inhibit testicular androgen synthesis. Serum testosterone may rise modestly while generally remaining within the physiological range. Its effects are tissue-dependent and do not constitute complete androgen suppression."
    },
    {
      "heading": "Clinical uses",
      "text": "Benign prostatic hyperplasia\n\nBenign prostatic hyperplasia is noncancerous enlargement of the prostate that can contribute to urinary symptoms. Finasteride is used particularly when prostate enlargement is present. The standard oral dose for this indication is 5 mg daily.\n\nOver time, treatment can reduce prostate volume, improve urinary symptoms, and lower the risk of acute urinary retention and the need for prostate-related surgery. Symptomatic improvement is gradual and may take several months. Finasteride does not immediately relax the smooth muscle of the prostate or bladder outlet, which distinguishes it from alpha-adrenergic blockers. These drug classes are sometimes used together.\n\nMale-pattern hair loss\n\nFinasteride is used for male androgenetic alopecia, a common cause of hair loss. The standard approved oral dose for this indication is 1 mg daily. Trials have demonstrated slower progression of hair loss and increased hair counts in some treated men, especially in studied areas of the vertex and anterior mid-scalp.\n\nResponse varies, and treatment does not reliably restore a full head of hair. Benefits generally require continued treatment; after discontinuation, the treatment-associated gains are progressively lost. Evidence for male-pattern hair loss does not establish effectiveness for unrelated conditions such as scarring alopecia or autoimmune hair loss.\n\nTopical finasteride preparations are authorized in some jurisdictions. Their regulatory status and formulations differ between countries. Systemic absorption is lower with some topical preparations than with oral treatment, but it is not absent, and topical administration does not eliminate all systemic or reproductive safety concerns."
    },
    {
      "heading": "Pharmacokinetics",
      "text": "After oral administration, finasteride is absorbed and undergoes extensive hepatic metabolism. Its plasma elimination half-life is approximately five to six hours in younger adults and is somewhat longer in older adults. Its suppression of DHT lasts longer than its presence in plasma alone would suggest.\n\nFinasteride is highly protein-bound, and its metabolites are eliminated in urine and feces. Its pharmacokinetic profile supports once-daily oral administration."
    },
    {
      "heading": "Adverse effects and safety",
      "text": "Sexual and reproductive effects\n\nRecognized adverse effects include reduced sexual desire, erectile dysfunction, and ejaculatory disorders, including reduced ejaculate volume. In controlled trials, these events were reported more often with finasteride than with placebo, although many participants experienced no such effects.\n\nPersistent sexual symptoms after discontinuation have been reported and are included in product information in some jurisdictions. Postmarketing reports do not establish how frequently persistence occurs or, by themselves, determine causation in every reported case. Reduced semen quality and male infertility have also been reported; improvement after discontinuation has been described.\n\nBreast tenderness or enlargement and hypersensitivity reactions are other recognized adverse effects.\n\nPsychiatric effects and persistent symptoms\n\nDepression, mood changes, and suicidal ideation are recognized in regulatory safety information for oral finasteride. In 2025, European regulators confirmed suicidal ideation as an adverse effect of finasteride tablets, with its frequency unknown.\n\nThe term post-finasteride syndrome is used to describe reports of persistent sexual, psychological, and physical symptoms following treatment. Reported symptoms and regulatory warnings are distinct from establishing a single, fully characterized syndrome with a validated diagnostic test, known incidence, or established biological mechanism. Research is complicated by differences in study populations, selection bias, and the limitations of spontaneous adverse-event reporting.\n\nPregnancy and fetal development\n\nFinasteride is contraindicated during pregnancy because inhibition of DHT formation can disrupt development of the external genitalia of a male fetus. Product labeling includes handling precautions for pregnant people regarding crushed or broken tablets. Intact coated tablets prevent ordinary contact with the active ingredient during normal handling."
    },
    {
      "heading": "Prostate-specific antigen and cancer research",
      "text": "Finasteride lowers blood concentrations of prostate-specific antigen (PSA), a biomarker used in evaluating prostate disease. With 5 mg treatment, PSA commonly decreases by about half within six months. Consequently, an unadjusted PSA result can be misleading if finasteride exposure is not taken into account. PSA changes during treatment require interpretation in relation to treatment duration and the established treatment baseline.\n\nThe Prostate Cancer Prevention Trial, a large randomized controlled trial, found fewer prostate cancer diagnoses among men assigned finasteride but also a higher proportion of high-grade cancers detected in that group. Subsequent analyses examined how reduced prostate size and changes in detection could contribute to this finding. Long-term follow-up did not demonstrate a significant difference in overall survival between treatment groups. Finasteride is not approved in the United States for prevention of prostate cancer."
    },
    {
      "heading": "Development and regulatory history",
      "text": "Finasteride was developed following research into androgen metabolism and inherited 5-alpha-reductase deficiency. The United States approved it for benign prostatic hyperplasia in 1992 and for male-pattern hair loss in 1997. Well-known brand names include Proscar for the 5 mg formulation and Propecia for the 1 mg formulation; generic products are widely available.\n\nIts approved indications, available formulations, and safety labeling vary by jurisdiction. Continued pharmacovigilance has led to updates concerning sexual and psychiatric adverse effects."
    }
  ],
  "links": [
    "benign-prostatic-hyperplasia",
    "enzyme",
    "prostate",
    "surgery",
    "hair-loss",
    "metabolism",
    "pharmacokinetics",
    "erectile-dysfunction",
    "placebo",
    "depression",
    "pregnancy",
    "biomarker",
    "randomized-controlled-trial",
    "prostate-cancer",
    "pharmacovigilance"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}